Advancing the Management of Prostate Cancer–Related Bone Disease

Release date: July 2010
Expiration date: July 31, 2011
Estimated time to complete activity: 2 hours

Jointly sponsored by Curatio CME Institute, the Bone and Cancer Foundation, and the Cancer and Bone Society.

This activity is based on information presented at a satellite symposium held on May 29, 2010 in San Francisco, California prior to the 2010 American Urological Association (AUA) Annual Meeting.

This activity is supported by an educational donation provided by Amgen.

This activity is offered in conjunction with BoneOncologyTX.com.

Hardware/Software Requirements

Javascript-enabled browser
Active high-speed Internet connection
Adobe Acrobat Reader
Adobe Flash Player 7.0+

Activity Overview
Prostate cancer is the most common newly diagnosed cancer in men. In the U.S., prostate cancer accounts for 25% of all new cancer diagnoses and 10% of all cancer deaths. Prostate cancer also has a high propensity for metastasizing to bone, at which time it is considered incurable and is associated with a high degree of morbidity and mortality. The increased bone loss and associated skeletal complications that result from cancer and cancer therapies are equally concerning, even in patients without metastasis. This activity discusses the current and emerging therapies used to improve the management of bone disease in men with prostate cancer. Emerging clinical trial data is also discussed.

Target Audience
This activity has been designed to meet the educational needs of urologists, urologic oncologists, medical oncologists, and other health care providers who manage patients with prostate cancer that has metastasized to bone or has the potential to metastasize to bone.

Learning Objectives
Upon completion of this activity, participants should be able to:

Describe the clinical impact of untreated bone loss on fracture risk, overall health, quality of life, and survival
Discuss mechanisms of bone loss and new therapeutic approaches for managing bone loss
Recommend appropriate screening methods and schedules to monitor for bone loss
Utilize evidence-based practices in the prevention and management of bone disease
Educate patients with clear, concise information on the risks associated with various bone-sparing agents and the risks of complications associated with a lack of treatment

Activity Faculty
Matthew R. Smith, MD, PhD—Chair
Associate Professor of Medicine
Harvard Medical School
Massachusetts General Hospital Cancer Center
Boston, Massachusetts

Celestia S. Higano, MD
Professor of Medicine
Division of Oncology and Department of Urology
University of Washington
Seattle, Washington

Joel B. Nelson, MD
Frederic N. Schwentker Professor and Chairman
Department of Urology
University of Pittsburgh School of Medicine
Pittsburgh, Pennsylvania

Fred Saad, MD, FRCS
Professor and Chief of Urology
Director of Urologic Oncology
University of Montreal Endowed Chair in Prostate Cancer
University of Montreal Hospital Centre
University of Montreal
Montreal, Quebec, Canada

Accreditation Statement
This activity has been planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint sponsorship of Curatio CME Institute, the Bone and Cancer Foundation, and the Cancer and Bone Society. Curatio CME Institute is accredited by the ACCME to provide continuing medical education for physicians.

Credit Designation
Curatio CME Institute designates this educational activity for a maximum of 2.0 AMA PRA Category 1 Credits™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

Method of Participation
There are no fees for participating in this CME activity. To receive credit during the period July 2010 to July 31, 2011, participants must (1) read the learning objectives and disclosure statements, (2) study the entire educational activity, and (3) complete the presurvey, postsurvey, and activity evaluation form.

The postsurvey and activity evaluation can be accessed at the end of the activity. Please e-mail any questions to cmeinfo@curatiocme.com.

Clinicians should not claim credit for this activity if credit was previously claimed for the symposium on which this activity is based.

Medium
This activity is offered as an Internet activity on BoneOncologyTX.com. Offering this CME activity online allows participants to learn on their own time and at their own pace. The interactive nature of the activity allows participants to become engaged and offers visual, written, and spoken education to suit many learning styles.

Disclosure
In accordance with the ACCME Standards for Commercial Support, all CME providers are required to disclose to the activity audience the relevant financial relationships of everyone in a position to control content of an educational activity. A relevant financial relationship is a relationship in any amount occurring in the last 12 months with a commercial interest whose products or services are discussed in the CME activity content over which the individual has control. Relationship information appears below:

Celestia S. Higano, MD, has disclosed the following relevant financial relationships:

Speaker

Amgen

Dr. Higano discusses the unlabeled or investigational use of a commercial product.

Joel B. Nelson, MD, has disclosed the following relevant financial relationships:

Speaker	Astra Zeneca
Consultant	Amgen, Millennium/Takeda, Roche

Dr. Nelson discusses the unlabeled or investigational use of a commercial product.

Fred Saad, MD, FRSC, has disclosed the following relevant financial relationships:

Speaker, Consultant

Amgen, Novartis

Dr. Saad discusses the unlabeled or investigational use of a commercial product.

Matthew R. Smith, MD, PhD, has disclosed the following relevant financial relationships:

Consultant

Amgen, GTx, Novartis

Dr. Smith discusses the unlabeled and investigational use of a commercial product.

Curatio CME Institute
Matthew Horn, MD, Medical Director, has disclosed no relevant financial relationships.
Jonathan S. Simmons, ELS, Managing Editor, has disclosed no relevant financial relationships.
Derek Warnick, CME Director, has disclosed no relevant financial relationships.

Bone and Cancer Foundation
Charlene Waldman, Executive Director, has disclosed no relevant financial relationships.

Cancer and Bone Society
Jeanette Ruby, Director of Development, has disclosed no relevant financial relationships.

Disclaimer
The information presented in this activity is for continuing medical education purposes only and is not meant to substitute for the independent medical judgment of a physician regarding diagnosis and treatment of a specific patient’s medical condition.

Unapproved Product Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the US Food and Drug Administration. Curatio CME Institute, the Bone and Cancer Foundation, the Cancer and Bone Society, and Amgen do not recommend the use of any agent outside the labeled indications.

The opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of Curatio CME Institute, the Bone and Cancer Foundation, the Cancer and Bone Society, or Amgen. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Generic Name	Trade Name	Approved Use (if any)	Unapproved/Investigational Use
Alendronate	Fosamax	Treatment and prevention of osteoporosis in women; treatment of osteoporosis in men; treatment of glucocorticoid-induced osteoporosis in men and women; Paget’s disease in men and women	Treatment and prevention of bone metastasis; treatment of cancer therapy–induced bone loss
Atrasentan	Xinlay	Investigational agent: novel endothelin-A antagonist	Treatment and prevention of bone metastasis; treatment and prevention of cancer therapy–induced bone loss
Clodronate	Bonefos	Treatment of hypercalcemia of malignancy (outside the U.S.; not approved by the US FDA)	Treatment and prevention of bone metastasis
Denosumab	Prolia	Investigational agent: novel RANKL antibody	Treatment and prevention of bone metastasis; treatment and prevention of cancer therapy–induced bone loss
Pamidronate	Aredia	Treatment of Paget’s disease, hypercalcemia of malignancy, and the osteolytic bone metastases of multiple myeloma and breast cancer	Treatment of bone metastasis in prostate cancer; prevention and treatment of cancer therapy–induced bone loss
Zibotentan (ZD4054)	N/A	Investigational agent: novel endothelin-A antagonist	Treatment and prevention of bone metastasis; treatment and prevention of cancer therapy–induced bone loss
Zoledronic acid	Zometa	Treatment of hypercalcemia of malignancy; multiple myeloma; solid tumors with documented metastasis to bone (in conjunction with standard antineoplastic therapy); prostate cancer that has progressed after hormonal therapy	Prevention of bone metastases; treatment and prevention of cancer therapy–induced bone loss

Policy on Privacy and Confidentiality
Curatio CME Institute collects the information provided by the user. The information is used to notify users about upcoming programs and educational information that may be of interest. The information is not shared or used for commercial purposes unless prior permission has been granted by the user.

Curatio CME Institute may collect standard Web traffic data such as time and date of visit. Curatio CME Institute uses this information to administer its Web site. Browsing activity is recorded to form aggregate and anonymous demographic information, which is used as described above. Curatio CME Institute does not sell or offer to sell any user data, including registration and billing information, to any third parties for commercial purposes. Curatio CME Institute does, when required, provide the minimum subset of information to third parties that are responsible for accreditation of and issuance of certification for CME/CE tests. By participating in the Web-based activity, the user agrees that Curatio CME Institute has full permission to provide this minimum subset of information to the third parties as required by law.

Curatio CME Institute